GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (NAS:ONC) » Definitions » 5-Year ROIIC %

ONC (BeiGene) 5-Year ROIIC % : 10.54% (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BeiGene 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. BeiGene's 5-Year ROIIC % for the quarter that ended in Dec. 2024 was 10.54%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for BeiGene's 5-Year ROIIC % or its related term are showing as below:

ONC's 5-Year ROIIC % is ranked better than
68.38% of 1281 companies
in the Biotechnology industry
Industry Median: -18.12 vs ONC: 10.54

BeiGene 5-Year ROIIC % Historical Data

The historical data trend for BeiGene's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene 5-Year ROIIC % Chart

BeiGene Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
5-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -135.01 -75.17 -92.56 -26.91 10.54

BeiGene Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.91 - - - 10.54

Competitive Comparison of BeiGene's 5-Year ROIIC %

For the Biotechnology subindustry, BeiGene's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeiGene's 5-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeiGene's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where BeiGene's 5-Year ROIIC % falls into.



BeiGene 5-Year ROIIC % Calculation

BeiGene's 5-Year ROIIC % for the quarter that ended in Dec. 2024 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -687.3503303 (Dec. 2024) - -966.9941934 (Dec. 2019) )/( 3157.924 (Dec. 2024) - 504.563 (Dec. 2019) )
=279.6438631/2653.361
=10.54%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


BeiGene  (NAS:ONC) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


BeiGene 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of BeiGene's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Executives
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Xiaodong Wang director C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Hillhouse Capital Advisors, Ltd. 10 percent owner OFFICE #122, WINDWARD 3 BUILDING, REGATTA OFFICE PARK, WEST BAY ROAD, GRAND CAYMAN E9 KY1-9006
John Oyler director, 10 percent owner, officer: Chief Executive Office C/O GENTA INC, 3550 GENERAL ATOMICS CT BLDG 9, SAN DIEGO CA 92121
Chan Henry Lee officer: SVP, General Counsel 55 CAMBRIDGE PARKWAY, SUITE 700W, CAMBRIDGE MA 02142
Lai Wang officer: Global Head of R&D C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Xiaobin Wu officer: President and GM China C/O MOURANT OZANNES CRP SVCS CAYMAN LTD, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Julia Aijun Wang officer: Chief Financial Officer C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Sanders Corazon (corsee) D. director C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Alessandro Riva director C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Margaret Dugan director C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Jane Huang officer: CMO, Hematology C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Amgen Inc 10 percent owner ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Howard Liang officer: CFO & CSO C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Timothy Yung-cheng Chen director LSI LOGIC CORP, 1621 BARBER LANE, MILPITAS CA 95035